These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31323004)

  • 1. Start low, go slowly - mental abnormalities in young prolactinoma patients under cabergoline therapy.
    Brichta CM; Wurm M; Krebs A; Schwab KO; van der Werf-Grohmann N
    J Pediatr Endocrinol Metab; 2019 Sep; 32(9):969-977. PubMed ID: 31323004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report.
    Casulari LA; de Castro LF; Kessler IM; Mendonça JL; de Fátima Magalhães Gonzaga M
    J Med Case Rep; 2019 Jun; 13(1):183. PubMed ID: 31202268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report.
    Koguchi M; Nakahara Y; Ebashi R; Ogata A; Shimokawa S; Masuoka J; Abe T
    J Med Case Rep; 2019 Jan; 13(1):18. PubMed ID: 30660191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
    Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
    Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
    Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical Management of a Prolactinoma in a 15-Year-Old Girl.
    Bowling MS; Zamudio A; Jaffery F
    J Pediatr; 2018 Sep; 200():287-287.e1. PubMed ID: 29685620
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of prolactinomas in children and adolescents; which factors define the response to treatment?
    Alikasifoglu A; Celik NB; Ozon ZA; Gonc EN; Kandemir N
    Pituitary; 2022 Feb; 25(1):167-179. PubMed ID: 34518999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
    Portari LHC; Correa-Silva SR; Abucham J
    Neuroendocrinology; 2022; 112(1):68-73. PubMed ID: 33477154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
    Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
    J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
    Shimon I; Benbassat C; Hadani M
    Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
    de Castro LF; Magalhães Gonzaga MF; Naves LA; Luiz Mendonça J; Oton de Lima B; Casulari LA
    Horm Res Paediatr; 2018; 89(1):63-70. PubMed ID: 28954263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
    Yarman S; Kurtulmus N; Bilge A
    Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR.
    Sosa-Eroza E; Espinosa E; Ramírez-Rentería C; Mendoza V; Arreola R; Mercado M
    Endocrine; 2018 Aug; 61(2):343-348. PubMed ID: 29948930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma.
    Montalvo I; Llorens M; Caparrós L; Pamias M; Torralbas J; Giménez-Palop O; Caixàs A; Palao DJ; Labad J
    Int Clin Psychopharmacol; 2018 Mar; 33(2):98-102. PubMed ID: 29035904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
    Shimon I
    Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.